Session » Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics III

Date: Wednesday, November 16, 2016

Time: 11:00AM-12:30PM

Meeting: 2016 ACR/ARHP Annual Meeting

11:00AM-12:30PM: Abstract Number: 3248

Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post-Hoc Analyses from the Scleroderma Lung Study I and II

11:00AM-12:30PM: Abstract Number: 3249

Improvement in Cough and Cough-Related Quality of Life in Participants Undergoing Treatment for Systemic Sclerosis-Related Interstitial Lung Disease

11:00AM-12:30PM: Abstract Number: 3246

Predictors of Long-Term Outcomes in Systemic Sclerosis Associated Pulmonary Arterial Hypertension from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry

11:00AM-12:30PM: Abstract Number: 3247

Safety and Efficacy of Belimumab with Background Mycophenolate for Early Diffuse Cutaneous Systemic Sclerosis: A Randomized, Placebo Controlled, Pilot Trial

11:00AM-12:30PM: Abstract Number: 3250

Serum MCP-1 Levels Predict Long-Term Progression of Interstitial Lung Disease in Systemic Sclerosis

11:00AM-12:30PM: Abstract Number: 3245

Surfactant Protein D and Krebs Von Den Lungen-6 Predict Severity of Systemic Sclerosis-Related Interstitial Lung Disease in Two Independent Cohorts

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].